JAMA vs The Lancet: Submission Strategy, Scope & How to Choose (2026)

JAMA asks: "Will this change how a practicing physician makes clinical decisions?"

JAMA's identity is pragmatic. The journal is published by the American Medical Association and reaches 340,000+ physicians. Papers need to move a reader from "I wasn't sure what to do" to "now I know." This means clinical trials with clear treatment implications, health-services research showing how to deliver care better, comparative effectiveness studies that resolve genuine clinical uncertainty, and implementation research bridging evidence to practice.

JAMA's statistical review is famously rigorous. Protocols and statistical analysis plans must align precisely with published claims. Inconsistencies between the registered protocol and the final analysis are caught and questioned. This is a strength if your statistics are rock-solid, JAMA's imprimatur validates the rigor. It's a hazard if your analysis evolved during the trial.

The Lancet asks: "Will this change health outcomes across populations and health systems?"

The Lancet's identity is global. Founded in 1823, it now reaches readers in 200+ countries. Papers need international or cross-system significance, evidence that matters whether you're a physician in London, Lagos, or Lima. Multi-country trials, Global Burden of Disease analyses, health policy research with implications across systems, and studies addressing health inequities in LMICs are core editorial territory.

The Lancet's fast-track option (peer review in 3-5 days, publication within 10 weeks) is unmatched among the Big 4 for time-sensitive research. If your findings are urgent, pandemic data, time-sensitive trial results, public health emergencies, The Lancet can move faster than any comparable journal.

Clinical decision papers. If the paper's primary value is helping a physician decide between Treatment A and Treatment B, JAMA's editorial lens is built for that question. The Lancet wants this too but weights international applicability more heavily.

Health-services and implementation research. How evidence reaches patients, how health systems deliver care more efficiently, how implementation gaps can be closed. JAMA has a genuine editorial interest in the operational side of medicine that The Lancet's more global focus sometimes overlooks.

Comparative effectiveness. Head-to-head comparisons of treatments, diagnostic strategies, or care delivery models. JAMA's readership of practicing physicians values practical answers to "which option should I choose?"

US-focused clinical work. If the study was conducted in US settings and the clinical implications are primarily for US practice (while generalizable in principle), JAMA is the more natural home. The Lancet wants the international angle to be genuine, not asserted.

International and multi-country work. If the paper's significance depends on showing patterns across countries, health systems, or populations, The Lancet is built for it. A trial in 15 countries showing different treatment effects by health-system context is a Lancet paper.

Global health equity. The Lancet's commitment to health equity and LMIC research is editorial, not decorative. Maternal mortality in sub-Saharan Africa, infectious disease interventions across Southeast Asia, NCD burden across income levels, these topics are core scope.

Urgent public health findings. The fast-track pathway (3-5 day peer review) is unmatched. When timing determines impact, The Lancet can deliver.

IF-sensitive career decisions. 88.5 vs 55.0 is a real gap for grant panels and promotion committees that weight these numbers.

Neither journal exists in isolation. Both have extensive family networks that catch papers too narrow for the flagship.

JAMA Network (12 specialty journals):

JAMA Internal Medicine, JAMA Oncology (IF 20.1), JAMA Cardiology, JAMA Neurology, JAMA Psychiatry, JAMA Surgery, JAMA Pediatrics, JAMA Dermatology, JAMA Ophthalmology, JAMA Otolaryngology, JAMA Network Open (~IF 15, OA at ~$3,000 APC). Papers desk-rejected from the flagship can be redirected to a specialty journal within the network.

Lancet family (24 specialty journals):

Lancet Oncology (IF 35.9), Lancet Infectious Diseases (IF 31.0), Lancet Digital Health (IF 23.8), Lancet Global Health (IF 19.1), Lancet Respiratory Medicine, Lancet Neurology, Lancet Psychiatry, and 17 others. The Lancet's family is larger than JAMA's, with more specialty coverage and generally higher IFs for the top specialty titles.

The strategic implication: Submitting to a flagship and getting transferred to a family journal is a legitimate publication strategy. A paper desk-rejected from The Lancet that lands in Lancet Oncology (IF 35.9) is still an outstanding outcome. Same for JAMA to JAMA Oncology (IF 20.1).

Sending a strong but US-clinical paper to The Lancet because 88.5 > 55.0. The paper is excellent (rigorous trial, clear clinical implication) but the editors don't see international consequence. The framing is about what US physicians should do, not about what changes across health systems globally. Desk rejection in 2 weeks.

The reverse: a genuinely international study submitted to JAMA because the authors are US-based and know the brand. The paper has multi-country data and cross-system policy implications that The Lancet's editors would prioritize, but JAMA's editors read it as a narrower clinical question.

The test: Read your abstract's conclusion. Does it say what doctors should do differently? JAMA. Does it say what changes across populations and systems? The Lancet.

Before choosing, a JAMA vs. The Lancet scope check can assess whether your manuscript reads as a clinical-decision paper (JAMA) or a global-consequence paper (The Lancet). The scan takes about 1-2 minutes and can prevent a 2-month misdirected submission cycle.

Both journals desk-reject 80%+ of submissions. Understanding the process helps set expectations.

At JAMA: A professional editor reads your manuscript and assesses whether it addresses a broad clinical question with clear decision-making implications. JAMA's editors are looking for clinical utility, "will this change what physicians do?" Papers that are scientifically excellent but don't change practice get desk-rejected. The statistical team also screens early, if protocol/SAP inconsistencies are visible on first read, the paper may not advance.

At The Lancet: Editors evaluate whether the research has international or cross-system significance. A multi-center US trial that is excellent but only relevant to US healthcare may be desk-rejected. The editors also evaluate whether the paper's framing matches The Lancet's editorial mission: improving global health with an equity lens.

Common reasons for desk rejection at both:

• Scope mismatch (the #1 reason at both journals)
• Insufficient sample size to be practice-changing
• Clinical question already definitively answered by prior literature
• Methods section reveals design weaknesses visible to editorial team
• Writing quality that signals the paper isn't ready for flagship review

After desk rejection: Both journal families offer internal transfers. A JAMA desk rejection may be redirected to JAMA Oncology, JAMA Internal Medicine, or JAMA Network Open. A Lancet desk rejection may be redirected to Lancet Oncology, Lancet Global Health, or another family journal. Accepting a transfer is often the right call, a Lancet specialty journal at IF 35+ is an outstanding outcome.

Both journals saw dramatic IF inflation during COVID:

• The Lancet peaked at 168.9 (2022), now 88.5
• JAMA peaked at 120.7 (2022), now 55.0

The current numbers are closer to pre-pandemic baselines. The gap between them (88.5 vs 55.0) is consistent with historical patterns where The Lancet's broader international readership generates more citations per paper. Neither journal is declining, both are normalizing from an anomalous period.

A JAMA vs. The Lancet scope check can help you identify which flagship fits your paper's framing before you enter the desk rejection lottery.